AVAH vs. EHAB, VMD, PNTG, HLTH, AHCO, ADUS, SRDX, PEPG, TALK, and RVNC
Should you be buying Aveanna Healthcare stock or one of its competitors? The main competitors of Aveanna Healthcare include Enhabit (EHAB), Viemed Healthcare (VMD), The Pennant Group (PNTG), Cue Health (HLTH), AdaptHealth (AHCO), Addus HomeCare (ADUS), Surmodics (SRDX), PepGen (PEPG), Talkspace (TALK), and Revance Therapeutics (RVNC). These companies are all part of the "medical" sector.
Enhabit (NYSE:EHAB) and Aveanna Healthcare (NASDAQ:AVAH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
Enhabit has higher earnings, but lower revenue than Aveanna Healthcare. Enhabit is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.
In the previous week, Enhabit had 5 more articles in the media than Aveanna Healthcare. MarketBeat recorded 12 mentions for Enhabit and 7 mentions for Aveanna Healthcare. Enhabit's average media sentiment score of 0.59 beat Aveanna Healthcare's score of 0.00 indicating that Aveanna Healthcare is being referred to more favorably in the news media.
88.0% of Aveanna Healthcare shares are owned by institutional investors. 1.9% of Enhabit shares are owned by company insiders. Comparatively, 7.8% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Aveanna Healthcare received 21 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 38.71% of users gave Aveanna Healthcare an outperform vote while only 13.04% of users gave Enhabit an outperform vote.
Aveanna Healthcare has a net margin of -7.10% compared to Aveanna Healthcare's net margin of -7.69%. Aveanna Healthcare's return on equity of 1.55% beat Enhabit's return on equity.
Enhabit currently has a consensus price target of $11.21, suggesting a potential upside of 36.02%. Aveanna Healthcare has a consensus price target of $1.80, suggesting a potential downside of 27.42%. Given Aveanna Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Enhabit is more favorable than Aveanna Healthcare.
Enhabit has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Aveanna Healthcare has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
Summary
Aveanna Healthcare beats Enhabit on 11 of the 18 factors compared between the two stocks.
Get Aveanna Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVAH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVAH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aveanna Healthcare Competitors List
Related Companies and Tools
